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Objective:
 
 A 1-year semi-Markov model was constructed
to simulate the cost-effectiveness of atypical and typical
antipsychotic treatments for schizophrenia.
 
Methods:
 
 The core model comprised nine 6-week cycles
and includes events such as survival, response, adverse
events, and compliance. The nature, duration, intensity,
and timing of adverse events were incorporated. Com-
pliance was modeled as a function of health state, time,
and adverse events. Three first-line treatments were
considered (risperidone, olanzapine, and haloperidol
oral) and the transition probabilities of switching be-
tween five different therapies (haloperidol oral, halo-
peridol depot, risperidone, olanzapine and clozapine)
were included. Effectiveness was modeled based on a
modified method of TWiST (time without symptoms
and toxicity). The direct costs of utilization of medical
resources are taken into account, including five dif-
ferent patient care settings, consultations, neuroleptic
medication, laboratory tests, and treatment of side-
effects.
 
Results:
 
 This paper reports the methodology used to
construct the model and the results obtained when it
was applied to the treatment of patients with schizo-
phrenia in the Belgian health care system.
 
Conclusions:
 
 Over the study period, risperidone and
olanzapine were more cost-effective than haloperidol
and of the two major atypical drugs, risperidone was
the more cost-effective.
 
Keywords:
 
 atypical antipsychotic, cost-effectiveness,
Markov model, olanzapine, risperidone, schizophrenia.
 
Introduction
 
Schizophrenia affects about 1% of the adult popu-
lation worldwide [1,2], placing a heavy social and
economic burden on both sufferers and society
[3,4]. The condition is characterized by disturbing
and unusual internal experiences, socially inap-
propriate behavior, and reduced participation in
social and occupational activities. Schizophrenia is
generally a progressive and lifelong illness requir-
ing on-going maintenance treatment to reduce the
incidence of psychotic relapses. Conventional neu-
roleptic drugs have been successful in controlling
positive symptoms (e.g., hallucinations, delusions,
and thought disorder), but do not prevent the on-
set and progression of negative symptoms (e.g.,
emotional apathy, social withdrawal, self-neglect,
and lack of initiative). Thus, patients tend not to
recover a normal level of social functioning and
rarely live a normal life. In addition 5–25% of
patients are resistant to treatment [5], or experi-
ence severe side-effects, particularly extrapyrami-
dal symptoms (EPS) such as Parkinsonism and
dyskinesias, which increase patient distress and re-
duce patient compliance, thus increasing the risk
of psychotic relapse.
Standard treatment for an acute episode of
schizophrenia comprises inpatient treatment with
follow-up provided by a range of outpatient ser-
vices. Long-term treatment of chronic schizophre-
nia usually involves maintenance medical therapy
with intensive family management and social, vo-
cational and cognitive rehabilitation strategies [6].
However, traditional neuroleptic treatments rarely
produce a full recovery, and many patients still
have considerable psychosocial and vocational dis-
abilities, incurring a significant economic burden to
society.
With the chronic course of schizophrenia and
the frequent instances of relapse, it is not surpris-
ing that treatment costs for this condition are high.
While health care spending accounts for about
10% of Gross Domestic Product in many developed
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countries [7], the direct costs alone for the treat-
ment of schizophrenia account for between 1.5
and 3% of the total health care budget [2,3,8–11].
In Belgium, the total direct costs are estimated to
account for 1.9% of the government’s health ex-
penditure, which means that the average expendi-
ture for a schizophrenic patient exceeds 10 times
the health care costs of the average citizen [4].
Given the prevalence of schizophrenia, together
with the early age of onset, pattern of chronicity,
and level of social impairment, models determin-
ing the cost-effectiveness of different treatments
provide valuable outcome measures and are essen-
tial to understanding the potential impact of new
therapies on the management of the illness [12].
Moreover, the development of a new class of atyp-
ical agents, including risperidone and olanzapine,
with improved efficacy on both positive and nega-
tive symptoms and improved tolerability profiles
compared with conventional neuroleptics, could
reduce the economic impact of schizophrenia [13].
This provides an imperative for a comparison of
the cost-effectiveness of treatments for schizophre-
nia. This study therefore constructed a model to
simulate the cost-effectiveness of atypical versus
typical neuroleptics in the treatment of schizo-
phrenia. A number of pharmacoeconomic analy-
ses in schizophrenia have been conducted, includ-
ing prospective cost analyses based on resource
utilization data, clinical decision analysis models,
and retrospective cost analyses [14].
A Markov model for atypical antipsychotics
was developed and applied for five countries [15].
This model estimated the total costs and effective-
ness outcomes for patients experiencing multiple
episodes of schizophrenia. It had the following prop-
erties: (1) follow-up period was 5 years; (2) effec-
tiveness measure was defined as amount spent with
a Brief Psychiatric Rating Scale (BPRS) total score
 

 
18 over the follow-up period; and (3) patients with
treatment-resistant schizophrenia were excluded.
The overall results of the above mentioned studies
indicated that despite higher acquisition costs of
atypical antipsychotics, initiation of treatment with
those drugs rather than haloperidol did not in-
crease the total treatment costs, while those drugs
were associated with a higher effectiveness. Out-
comes from the model were rather insensitive to the
different local treatment patterns and health care
financing systems. Analyses between atypical an-
tipsychotics did not show substantial differences
in cost-effectiveness outcomes between an initial
treatment with risperidone versus olanzapine. This
Markov model design had several weaknesses. Var-
 
ious data sources were used which all had pros
and cons [16] from a health economic perspective.
For example, the clinical data included in the model
was mainly derived from clinical trials, which do
not necessarily have a high degree of external va-
lidity since the results are often contingent upon
protocol adherence, a situation not easily replicated
outside the trial setting. For instance, the compar-
ative trial with risperidone used in the model has
been criticized for being disadvantageous to ris-
peridone, particularly with respect to the dosage
schedule, which may have aggravated EPS [14]. Fi-
nally, the clinical trials were of inadequate dura-
tion, varying between one month and 12 months.
Therefore the clinical data required extrapolation
to a 5-year time horizon, introducing another source
of uncertainty.
Therefore, a model was constructed comprising
a 1-year core to simulate the cost-effectiveness of
atypical versus typical neuroleptics in the treat-
ment of schizophrenia, which was intended to cor-
respond more closely with real life by optimizing
the external validity. Decision analysis techniques
were used to estimate the cost-effectiveness of two
atypical agents, risperidone and olanzapine, and a
typical neuroleptic, haloperidol, in the treatment
of schizophrenia. Haloperidol has been the stan-
dard treatment for schizophrenia for many years.
 
Methods
 
The model describes a hypothetical population of
patients suffering from chronic schizophrenia who
are hospitalized for an acute exacerbation of psy-
chotic symptoms with a Positive and Negative
Syndrome Scale (PANSS) score [17] in the range
60–120 and a Clinical Global Impression scale
(CGI) score [18] of 5 or higher. All direct medical
costs of treatment were evaluated over a 1-year
period in the current health care setting in Belgium,
using the perspective of the Rijksinstituut voor
Ziekte en Invaliditeits Verzekering/Institut National
Assurances Maladies et Invalidité (RIZIV/INAMI),
the health insurance system.
The model was based on data from the litera-
ture, guidelines from the American Psychiatric As-
sociation (APA) [19], and discussions with experts,
using the Delphi method [20] and it was built us-
ing the decision tree software DATA
 
TM
 
 3.0.16 from
TreeAge Software Inc. (Williamstown, MA, USA).
 
Model Design
 
Treatment of schizophrenia was simulated using a
Markov process [21–24]. The choice for a model-
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ing design was due to limited duration and exter-
nal validity of existing clinical trials. Modeling
shows the consequences and complications of dif-
ferent therapeutic interventions in the real situation
of schizophrenia in Belgium. A Markov model
provides a convenient method of modeling the
long-term evolution of health states over succes-
sive time periods, where events recur over time
and where patients move along a finite number of
health states during the time period under consid-
eration [22]. A Markov process model describes
several discrete states of health over sequential pe-
riods called cycles. The progression from t 
 

 
 
 
n
 
 to
t 
 

 
 
 
n
 
 
 

 
 1 is called a cycle. All clinically important
events are modeled as transitions from one state to
another state. The Markov process may capture
the cyclical nature of schizophrenia and the associ-
ated time-dependent outcomes, as patients with
schizophrenia are subject to relapses and the num-
ber of possible health states is finite. In a Markov
model, however, the transitions only depend on
health state and time, while transitions in schizo-
phrenia may also depend on covariables such as
past clinical history, reasons for a previous treat-
ment failure (such as poor efficacy or side-effects),
or type of treatment. Therefore, this study ex-
tended the Markov model to a semi-Markov model,
which allowed more realistic simulation of disease,
incorporating all relevant variables in real life.
The time frame of the model was 1 year, di-
vided into nine 6-week cycles (1.04 years). A cycle
time of six weeks was chosen since this interval
closely approximated the time required to assess
efficacy in real life. The possibility of death due to
suicide during the time frame was also considered,
because 0.6% of patients with schizophrenia com-
mit suicide during a 1-year period in Belgium [25].
Since the time frame was restricted to 1 year, dis-
counting of costs was not employed.
All patients started in the Markov state of acute
exacerbation and were hospitalized and treated with
one of the three first-line treatments assessed: ris-
peridone 5 mg/day, olanzapine 15 mg/day, or halo-
peridol oral 10 mg/day (Fig. 1). The doses chosen
represented the most recent view of average daily
doses with equivalent clinical effect [26,27]. The
branching points that followed these treatment op-
tions were chance nodes and corresponded to the
different situations that a patient could experience
during each cycle. Five outcomes were addressed for
each cycle: survival, response, incidence of adverse
events, whether these adverse events were bearable,
and compliance. Response, defined as an improve-
ment in symptoms that supports the continuation of
treatment, was determined for each cycle, based on
the level of improvement in PANSS and CGI scores
versus the initial scores (cycle 0) (see Table 1).
Based on the definitions of response and relapse
(Table 1) and on the APA guidelines [19], four dis-
crete health states were distinguished: acute phase
or relapse, stabilization, stable phase, and death.
These were mutually exclusive and collectively ex-
haustive. The model allowed switching between
five different therapies: haloperidol oral, haloperi-
dol depot, risperidone, olanzapine, and clozapine.
 
Model Assumptions
 
Information on therapeutic choices and treatment
alternatives, transition probabilities between health
states, utilization of health care resources in each
health state, the probabilities of patient compli-
ance, and incidences of side-effects was derived
from the literature. When no data were available
in the literature or from clinical trials, the infor-
mation (see Table 2) was gathered from members
of an expert panel of 10 Belgian psychiatrists us-
ing the Delphi method [20]. This method, in which
a panel of experts is asked to provide a conver-
gence of opinion in an iterative process, is vali-
dated and well accepted where used appropriately
[28,29].
Adverse events considered in the model were an-
ticholinergic and haematological effects, dystonia,
akathisia, Parkinsonism, neuroleptic malignant syn-
drome, tardive dyskinesia, seizures, galactorrhoea,
oligomenorrhoea, orthostatic hypotension, weight
gain, sedation, and disturbances in sexual func-
tion. Adverse events were ignored when they were
deemed to be infrequent and have no impact on
compliance, provided they did not have significant
impact on resource use (e.g., allergic, hepatic, and
ophthalmologic effects). Each adverse event was di-
vided in two groups, bearable and unbearable (for
definitions, see Table 1). Rates of adverse events
and compliance were derived by the Delphi panel
and cross-checked with literature data when avail-
able to see whether they fell in the range of accept-
ability. In the final round of the Delphi process, the
panel of experts assigned a consensus level of confi-
dence to each estimation. Table 3 lists the assump-
tions made in the construction of the model regard-
ing the patient population, the progression of the
disease, choice of treatment, and use of resources.
These assumptions were discussed and agreed with
the Delphi panel.
Although disease progression may be related to
the setting (e.g., whether or not the patient is in a
psychiatric hospital or is an outpatient), it was as-
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sumed in the model that each of the treatment
strategies was equally distributed between the dif-
ferent settings. Thus, the model made the assump-
tion that disease progression depended only on the
drug administered.
The Delphi panel established the probabilities
of switching drugs and which second or third line
therapy to use based on standard Belgian practice.
The probabilities of switching depended on the re-
sponse, the presence of adverse events, and com-
pliance. A switch to another treatment was made
in all cases of no response, or where unbearable
side-effects were present. When response was as-
sociated with bearable side-effects but the patient
was noncompliant, it was assumed 50% of pa-
tients will continue with the current treatment and
50% will switch to another neuroleptic. The Del-
phi panel decided the probability of subsequent
choices of neuroleptic once the decision to change
had been made. To determine the choices for the
first and subsequent switches the Delphi panel
considered 10 hypothetical patient profiles, in-
cluding all combinations of responders and nonre-
sponders, compliant and noncompliant patients,
each with adverse events classed as absent, bear-
able, or unbearable. Table 4 shows the range of
probabilities generated for the relevant scenarios
at the first requirement to switch therapy.
If the initial therapy is one of the newer atypi-
cals, then the choice at first switch is the other
Figure 1 Basic design of model, showing
the decision tree for only one therapeutic
choice over one cycle:  decision node;
 chance node;  terminal node.
Table 1 Definitions relating to the outcome of treatment
 
Response • An improvement in symptoms which leads to the continuation of treatment*
No response • No improvement in symptomatology, or relapse which leads to re-evaluation of the choice of treatment 
and hospitalization
Relapse • Non-response after at least 18 weeks (3 cycles) of response
Resistance to treatment • A patient is considered resistant to treatment after failing on three different therapies
Bearable side effect • A side effect that is bearable to the patient with or without treatment for the side effect
Unbearable side effect • A side effect that is life threatening or unbearable to the patient even with treatment for the side effect
Non-compliance • Discontinuation of treatment
 
*Actual minimum changes in PANSS and CGI scores to be considered as improvements were decided by the Delphi panel (minimum decrease of 30% in PANSS and
a minimum decrease of 2 points in CGI, both versus the initial score at cycle 0).
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atypical in 65–90% of patients. It was assumed
throughout that risperidone and olanzapine have
equal safety and efficacy profiles. This assumption
is consistent with published meta-analyses and
comparative trials of risperidone and olanzapine,
which fail to demonstrate a significant clinical dif-
ference between the drugs [26]. Once all three
agents were tried, patients were switched to cloza-
pine. Clozapine is also used in 83–90% of patients
instead of haloperidol after both newer atypicals
have been tried as the first two therapies. When
one of the newer atypicals and haloperidol were
used, clozapine was used in preference to the other
atypical in 5–38% (usually 10%) of cases.
The Delphi panel estimated that 10% of pa-
tients became noncompliant during each acute cy-
cle, and that this percentage would increase dur-
ing stabilization (17%) and stable (23%) cycles.
Introduction of depot haloperidol improved com-
pliance to 94%. The presence of adverse events
was associated with a significant drop in compli-
ance during a cycle, particularly if the adverse
event is rated as unbearable (Table 5). The Delphi
panel estimated the probability and severity of ad-
verse events for each cycle. As described earlier,
emphasis was placed on those adverse events that
were frequent or likely to affect patient compli-
ance. Cost of treating other adverse events was
based on allocating resource (e.g., antiParkinson
treatment) for the full cycle of 42 days. Where ad-
verse events (e.g., sexual dysfunction, sedation,
tardive dyskinesia) required the switch to a new
neuroleptic during the cycle, the costs of the new
agent were added for 21 days of that cycle.
The Delphi panel estimated the probabilities of
transitions between health states, taking into ac-
count underlying causes of nonresponse such as
adverse events and noncompliance. The assump-
tions, based on the consensus of a group of experi-
enced Belgian psychiatrists were easily changed to
allow the model to be applied to other countries
and health care practices.
 
Effectiveness Assessment
 
The measures of effectiveness were based on a
modified method of TWiST (time without symp-
toms and toxicity) [30]. Since most patients with
chronic schizophrenia have a residual level of
symptoms and side-effects, even in the stable phase,
it is more realistic to aim for a minimum level of
disease symptoms and a minimum level of side-
effects (cycles with minimum symptoms and toxic-
 
Table 2
 
Variables estimated by expert Delphi panel
 
• Probabilities of transition between health states
• Health care utilization per cycle for each health state, including:
• Number of consultations with a psychiatrist, GP, or 
psychotherapist
• Percentage of patients in hospitalization, sheltered housing*, 
normal housing
 
†
 
, sheltered housing with day hospital attendance, 
normal housing with day hospital attendance
• Number of days per week in day hospital attendance
• Type of medication taken and therapeutic choices for first-, 
second- and third-line therapy, as a function of 10 different
patient profiles
• Estimates of patient compliance, as a function of health state,
time, and adverse events
• Probability, nature, duration, and intensity of side effects, and as a 
function of time
• Nature and duration of treatment for side effects
 
‡
 
• Number of laboratory tests performed
 
*Costs of sheltered housing to the Belgian health care system are for a full
week, regardless of actual occupancy.
 
†
 
Hotel costs for normal housing are not covered by the Belgian health care
system.
 
‡
 
Data from the Delphi panel were supplemented by treatment guidelines pro-
duced in Belgium [26].
 
Table 3
 
Assumptions made in the model
 
• The starting population comprised patients with chronic schizophrenia aged 18-65 years, with a PANSS score of between 60 and 120 and a 
CGI score 
 

 
5, hospitalized for an acute exacerbation.
• The average baseline dosages for the drugs considered were 5 mg/day (range 4–6 mg/day) for risperidone, 15 mg/day (range 10–20 mg/day) 
for olanzapine, 10 mg/day (range 5–15 mg/day) for haloperidol, and 450 mg/day (range 300–600 mg/day) for clozapine.*
• For patients in the stabilization or stable phase, the dosage used for the first 6 months (4 cycles) is the same as that which prevented relapse. 
In the case of maintained response, the dosage is reduced by 20% every 6 months.
• After each cycle, the level of improvement in PANSS score and/or CGI score is compared with the initial score (at cycle 0) to determine 
whether or not the patient is responding.
• Distinction between the acute/relapse and stabilization/stable phases depends on the percentage changes in CGI and PANSS score from 
baseline.
• Distinction between stabilization and stable phases depends on the number of cycles spent with response.
• Patients require full-time hospitalization in a psychiatric hospital in the case of non-response or relapse.
• Combination treatment with more than one antipsychotic drug is not permitted due to the increased probability of side effects.
• For each treatment, the overall probability of a side effect is independent of the response of the patient to treatment.
• Patients in relapse receive as first-line treatment the antipsychotic to which they responded previously.
• The use of resources in a particular health state (e.g., acute or stable phases) is not a function of the drug received, but of the health state 
(except in the case of clozapine where frequent blood tests are required).
 
*Only for non-responders (resistant patients).
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ity, CWMST). Hence, the endpoint “time with
minimum symptoms and minimum toxicity,” dur-
ing a period of 1 year, represents the expected av-
erage number of cycles spent by the patients in the
health states “response with no side-effects” and
“response with bearable side-effects.” This can
also be expressed as the average time spent in
these health states over the 1-year period.
 
Cost Assessment
 
The Delphi panel participants estimated the utili-
zation of medical resources for each of the health
states. Patients in acute exacerbations and relapse
spent the whole cycle in hospital. In the stabiliza-
tion and the stable phases, only 13.6% spent the
cycle in hospital, 43.7% were in normal housing,
and 11.7% in sheltered accommodation. Of those
using day care hospitals (31% of all patients),
42.6% lived in sheltered housing and the remain-
der in normal housing. Sheltered housing was as-
sociated with a higher number of nursing contacts
(Table 6). Patients on clozapine required 1.5
blood tests per cycle.
All direct costs were evaluated over the time
frame of the model, including setting (i.e., hospi-
talization, sheltered housing, normal housing, shel-
tered housing with day hospital attendance, and
normal housing with day hospital attendance), con-
sultations, medication, laboratory tests, and treat-
ment of side-effects. The costs were obtained from
official tariff lists [31] and referred to 1998 prices.
Tables 7 and 8 give the key direct health care costs
derived from the tariffs. These reflect the prices
that health insurance has to pay and ignore the
patient’s contribution, which can be as high as
40% (e.g., for the cost of a visit to a psychiatrist).
The model reflects a survey in 1996 of patients in
Belgian psychiatric hospitals, which showed that
47% of such patients had VIPO/WIGW (Veuves,
Invalides, Pensionés, Orphelins/Weduwen, Inval-
iden, Gepensioneerdenen Wezen) status, which
markedly reduces the patient contribution, in-
creasing the cost to the third-party payer [32].
Thus, a visit to a psychiatrist for a person with
VIPO status cost the health care system 1044 BEF,
compared to 683 Belgian francs (BEF) for a non-
exempt person. In each case the patient made up
the cost to the “public price” of 1118 BEF.
Overnight stay in a psychiatric hospital cost the
RIZIV 5098 BEF per diem, whereas each visit to a
day hospital cost the RIZIV 3569 BEF. Sheltered
housing had a daily cost of 783 BEF. Nights spent
in ICU for treating neuroleptic malignant syn-
drome varied from 9243 to 11,296 BEF, depend-
ing on reimbursement status and location.
Daily costs of antipsychotic medication (Table
8) were independent of the patient’s reimburse-
ment status if the drugs were prescribed in hospi-
tal or at a day care hospital. Patients in the com-
 
Table 4
 
Probability of choice of second-line therapy after failure with initial therapy (switching strategy)
 
Initial Therapy Second-line Therapy Lack of Response (%)(6 scenarios)
Unbearable AEs (%)
(4 scenarios)
Non-compliance (%)
(4 scenarios)
Risperidone Olanzapine 65–80 80–85 65–80
Haloperidol 20–35 15–20 20–35
Olanzapine Risperidone 70–80 75–90 65–90
Haloperidol 20–30 10–25 20–35
Haloperidol Risperidone 50 50–60 50–60
Olanzapine 50 40–50 40–50
 
Table 5
 
Impact of adverse events on compliance over one 
cycle
 
Reduction in compliance (%)
Adverse event Bearable Unbearable
Anticholinergic effects 35.6 62.2
Dystonia 27.8 79.4
Akathisia 24.4 68.3
Parkinsonism 33.9 52.8
Neuroleptic malignant syndrome 36.3 100
Tardive dyskinesia 41.7 61.1
Seizures 27.5 92.2
Galactorrhea and Oligomenorrhea 37.8 75.6
Orthostatic hypertension 37.8 61.1
Weight gain 37.2 60.0
Hematologic 16.3 91.1
Disturbed sexual function 40.0 70.0
Sedation 28.8 76.3
 
Table 6
 
Consultations for patients in sheltered and normal 
housing
 
Sheltered housing Normal housing
% of
patients Mean/cycle
% of
patients Mean/cycle
General practitioner 46.9 1.0 36.9 1.0
Psychiatrist 82.0 2.0 86.7 2.0
Psychotherapist 17.0 2.0 19.6 2.0
Other (e.g., nurse) 37.9 5.0 9.1 1.5
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munity paid more towards the cost of their drugs
if they did not have VIPO/WIGW status.
 
Results
 
Table 9 summarizes the base case analysis over the
9 cycles (378 days). Selecting risperidone, haloperi-
dol, or olanzapine as first line treatment resulted in
total expected direct medical costs to the health in-
surance system of 1,137,700 BEF, 1,142,000 BEF,
or 1,151,900 BEF, respectively. At current ex-
change rates, these translate to annual costs of US
$36,125 for risperidone, US $36,262 for haloperi-
dol and US $36,574 for olanzapine. Risperidone
or olanzapine as first line treatment gave patients
69.4% of their time with minimum symptoms and
minimum toxicity, so risperidone was more cost-
effective than olanzapine in that it achieved the
same effect for a lower cost. Risperidone was
dominant over haloperidol (greater effect at lower
cost). Olanzapine, while also more effective than
haloperidol, cost more to achieve this effect.
 
The major cost drivers were hospitalization and
consultation, accounting for more than 90% of
the total expected cost (see Fig. 2). Drug acquisi-
tion costs accounted for 3.6% (haloperidol), 4.3%
(risperidone), and 5.5% (olanzapine) of the total
yearly cost.
 
Sensitivity Analysis
 
Sensitivity analyses were performed on key values
in the model that influenced either the cost or the
effectiveness outputs. Changes to the cost ele-
ments confirmed the results were robust, with ris-
peridone remaining the optimal choice. In con-
trast, slight modifications to the response rates
could have affected the choice of optimal strategy.
 
Daily Hotel Cost in Hospital.
 
Base case cost per
day was 5098 BEF; increasing or decreasing this
by 
 

 
 20% does not affect the order of preference
of the strategies, but does change the total cost per
strategy by 
 

 
 14.6%.
 
Daily Drug Price Per Mg.
 
Sensitivity analysis of
acquisition costs varied the price per mg reim-
bursed by RIZIV by 
 

 
 50% for each drug. Price
was a sensitive parameter for risperidone and
olanzapine but not for haloperidol. With a price
40% lower compared to the base case, olanzapine
became the cheapest strategy. Sensitivity analyses
of price on the cost-effectiveness ratios (BEF/
CWMST, Table 9) showed that risperidone re-
 
Table 7
 
Costs to third-party payer of consultations for 
ambulatory and hospitalized patients (BEF)
 
Patient status
Intervention VIPO* (n) Normal (n)
Visits to a general practitioner 363 276
Visits to a psychiatrist 1044 683
Sessions of psychotherapy
(at least 45 minutes) 1656 1395
Psychiatric consultations in
psychiatric hospital during
first 5 days hospitalization
 
†
 
698–908 498–708
Psychiatric consultations in
psychiatric hospital from
days 6–60 of hospital stay
 
†
 
262–360 171–234
Psychiatric consultations in
psychiatric hospital from
months 2–6 of hospital stay 115 75
Psychiatrist consultation in
psychiatric hospital from
month 7 of hospital stay 82 54
Blood tests 523 523
 
*Widow, invalid, retired, orphan.
 
†
 
Extremes represent two levels of service.
 
Table 8
 
Daily cost of neuroleptic drugs to the Belgian 
health care system (BEF)
 
Daily
dose
(mg)
Patients in the
community
Hospital
day care
Hospital
full time
Drug VIPO* Normal
 
†
 
All patients All patients
Risperidone 5 127.0 122.8 130.49 120.92
Haloperidol 10 32.4 28.6 26.33 21.37
Olanzapine
 
‡
 
15 248.6 239.7 256.19 235.69
Clozapine 450 154.4 136.3 140.27 114.65
 
*Widow, invalid, retired, orphan.
 
†
 
The insured cannot take advantage of any preferential reimbursement schedule.
 
‡
 
Based on Luxembourg prices as olanzapine was not available in Belgium at the
time of the study.
 
Table 9
 
Comparison of the three initial strategies: cost-effectiveness results over 9 cycles (all numbers rounded)
 
Paired comparison of
first line therapies
Costs (BEF) Effectiveness (CWMST)*
ConclusionTotal Incremental Total (%) Incremental
Risperidone 1,137,700 6.25 (69.4) Risperidone dominates
haloperidolHaloperidol 1,142,000 4,310 6.06 (67.3)
 

 
0.19
Risperidone 1,137,700 6.25 Risperidone dominates
olanzapineOlanzapine 1,151,900 14,195 6.25 0
 
*CWMST 
 

 
 cycles with minimum symptoms and toxicity.
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mained the most cost-effective treatment until its
price per mg was increased by 60%. If the olanza-
pine price per mg was decreased by 31% the ris-
peridone and olanzapine strategies became equally
cost-effective, assuming nothing else changed.
 
Daily Dose.
 
Base case daily doses were 5 mg/day
for risperidone and 15 mg/day for olanzapine.
Variation of these doses showed that risperidone
doses below 7.3 mg/day continued to be less costly
than haloperidol. Increasing the daily dose by
60% (to 8 mg) left risperidone as the most cost-
effective strategy of the three. Reducing the olan-
zapine dose by 33% to 10 mg/day still maintained
the olanzapine strategy as the most costly. Al-
though a 10-mg daily dose of olanzapine reduced
the cost-effectiveness advantage of risperidone, it
did not eliminate it. The difference in cost/
CWMST between the two therapies reduced by
48% (2260 BEF/CWMST to 1180 BEF/CWMST).
(Fig. 3)
 
Response Rates.
 
Sensitivity analysis of response
rate shows that the response rates in the first cycle
were critical to the order of economic efficiency of
the three strategies modeled. Sensitivity analyses
of response rates in subsequent cycles showed
these rates were not so sensitive. Reducing the ris-
Figure 2 Components of direct medical
costs for the three strategies over 9 cycles
(total direct medical costs expressed in
1000 BEF).
Figure 3 Sensitivity analysis of the im-
pact of change in average daily dose of
olanzapine on relative cost-effectiveness
of the three treatment strategies.
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peridone response rate from the base case of 68%
to 66.3% or increasing the olanzapine response
rate from 68% to 69.5% in the first cycle ren-
dered the strategies equally cost-effective. For ha-
loperidol to become equally cost-effective to ris-
peridone the response rate would have to increase
from the base case of 54% to 61%.
 
Discussion
 
There are few economic studies comparing the cost-
effectiveness of the new atypical agents such as ris-
peridone or olanzapine with conventional neurolep-
tics or with each other. This cost-effectiveness model
has been developed to provide these data. The analy-
sis of treatment over a 1-year period was judged to
be long enough to cover all phases of schizophrenia,
including acute, stabilization and stable phases, and
relapse and allow for death and suicide. Ideally such
models should also incorporate indirect costs. In
schizophrenia both these costs are very high, but
their estimation suffers from methodological prob-
lems and the focus of third-party payers in European
socialized medicine rarely goes beyond direct costs
[33]. This study therefore chose to concentrate on di-
rect costs, particularly payments made by the Bel-
gian health care system, while still recognizing the
enormous costs to patients and society from this
chronic and debilitating illness.
The model allows the assessment of clinical ef-
fectiveness and the economic costs associated with
the three strategies studied. Given the particular
nature of the disease course in schizophrenia, with
the knowledge that relapse can occur and that
many patients even on existing therapy are not
symptom free, the use of the number of cycles
with minimum symptoms and minimum toxicity
provids an easily understandable measure of effec-
tiveness.
Both atypical strategies demonstrate significant
clinical and economic superiority over haloperi-
dol, which suggests that atypical antipsychotics
should now be regarded as first line treatment in
preference to conventional neuroleptics [34]. Since
the cost of new therapies is frequently an issue, it
is noteworthy that the least expensive of the three
strategies examined (in terms of total direct medi-
cal costs) is the use of risperidone first line. First
line olanzapine is the most expensive, costing
14,195 BEF more than risperidone over the 9 cy-
cles modelled. Drug acquisition costs vary from
3.6 to 5.5% of direct costs, consistent with other
studies, which emphasize the predominance of
hospital costs [3,4,10,33].
Changes in hotel and consultation costs broadly
affect the three strategies in the same way. Changes in
drug costs are of greater interest, albeit they represent
a small fraction of total direct costs. Risperidone
costs would have to increase to 175–182 BEF/day
(US$5–5.2) before it became more expensive than ha-
loperidol and to more than 200 BEF/day (US$5.71)
before it lost its position as the most cost-effective of
the three initial treatments. Such large increases in the
average daily cost (e.g., by increasing the dose from 5
to 8 mg/day) are not recommended on clinical or
economic grounds. The World Health Organization
(WHO) recommended “defined daily dose” as 5 mg/
day and most patients are treated with 4–6 mg/day
[26]. Reducing the olanzapine dose to the lower end
of the recommended range (10 mg/day) is insufficient
to remove the cost-effectiveness advantage of risperi-
done. In addition, as experience is gained with olan-
zapine, somewhat higher doses are the trend [35].
Sensitivity analyses carried out on response rates
reveal that response rate is an extremely sensitive
variable; slight modifications could change the choice
of the optimal strategy. Because this study assumed
the safety and efficacy profiles of risperidone and
olanzapine to be the same, it is not surprising that a
small shift in their response rates relative to each
other would reverse their positions. From a clinical
perspective no convincing differences have emerged
between the two drugs that would suggest a different
set of assumptions for olanzapine than those used for
risperidone [26].
This model improves on the few previous eco-
nomic analyses of atypical antipsychotics (e.g., Palm-
er et al. [15]) in several key respects improving the
external validity. A definition of response was used
based on both the PANSS and CGI scores, provid-
ing a more global measure compared to the BPRS
used by Palmer et al. [15] Furthermore, the opportu-
nity of decreasing dosage after 6 months in the case
of response, in accordance with APA guidelines was
taken into consideration. A cycle length of 6 weeks
was used because this interval closely approximates
the time required to assess the efficacy of drug treat-
ment in schizophrenia. Other models in schizophre-
nia have used a cycle length of 3 months to assess the
cost-effectiveness of treatment for longer periods
[15,35,36]. Shorter, more frequent cycles more
closely follow clinical practice for assessment of pa-
tients and allow the model to respond more sensi-
tively to changes in patient state, reflecting real life.
When comparing drug treatments, attention
must be paid to the dosages used, which should be
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those used in clinical practice [26]. Moreover, they
should reflect the changing pattern of prescribing
throughout the course of the disease. In this model,
the doses used in the base-case scenario (e.g., ris-
peridone 5 mg/day, olanzapine 15 mg/day) were
representative of real life usage [19,26,37–40]. In
contrast, the dosages used in the base-case com-
parison in other studies [15] did not reflect the
dosages that have been established in real practice
and clinical trials [39,40]. The single trial [41] on
which the studies by Palmer et al. [15] and Al-
mond and O’Donnell [35] are based has been crit-
icized for having used a dose of risperidone that
was too high [42]. Furthermore, it is clear that the
dose of olanzapine used in clinical practice is fre-
quently higher (mean 15.8 mg/day; median 15 mg/
day) [15] than both the recommended routine
therapeutic dose and the doses used in clinical trials.
Because it was difficult to find reliable long-
term data for all the drugs assessed in this model,
the time horizon of this study was limited to 1
year rather than trying to extrapolate for 5 years
as previous authors have attempted [15,35].
Introduction of new atypical agents will have a
major economic impact [43] on the treatment of
schizophrenia, but given that health care budgets,
both within mental health care and for overall health
care, are becoming more constrained worldwide, the
attendant economic consequences of treatment
should be considered together with the clinical out-
come.
Although the model has been adjusted and vali-
dated by an expert panel of Belgian psychiatrists to
reflect local treatment patterns in Belgium, a key el-
ement of the design of this model is its portability
to other countries and health care systems. By using
appropriate, locally relevant data or opinion about
treatment patterns and resource use and applying
national costs, the conclusions may be recalculated
to enable other third-party payers (e.g., the Na-
tional Health Service in the UK) to determine the
most cost-effective strategy for them for the treat-
ment of this expensive group of patients.
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